Natalizumab update: anti-JCV Ab testing and PML risk


REPORT FROM THE AMERICAN ACADEMY OF NEUROLOGY (AAN) ANNUAL MEETING, SAN DIEGO, CA, MARCH 16-23, 2013 – A second-generation STRATIFY assay produces a lower false-negative rate and less variability in serostatus results compared to the original STRATIFY-1 test, according to the latest data.

It takes 30 seconds

Recommend to a Colleague

Related Posts

Go back to home page